Metrics cut 1
- Parshla and Amtra full commissioning delayed from start of FY27 to Q2-Q3 FY27, with meaningful revenue contribution expected only from H2FY27
Event Participants
Executives
2 Aryan Sehgal, Santosh Agarwal
Analysts
8 Aditya, Bhavya Doshi, Jasdeep Walia, Kiran, Nikhil Upadhyay, Nishita, Rahul Jain, Rushabh Shah
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹110.2 crore | +20.7% YoY; fastest Q1 growth, driven by domestic recovery and export rebound |
| Standalone Revenue | ₹86.1 crore | +21% YoY vs ₹71.3 crore in Q1FY26; highest ever Q1 standalone revenue |
| Domestic Sales Growth | +17% YoY | Supported by distribution network, customer engagement, and improving demand conditions |
| Exports (from India) Growth | +29% YoY | Healthy recovery post West Asia disruption and tariff uncertainty; inquiry-to-order conversion improving |
| German Subsidiary (Nurbe) Revenue | ~+6% YoY (constant currency) | Resilient performance in challenging operating environment |
| Gross Margin (Standalone) | 67.1% | Down ~450-500 bps on material margin due to 25-50% polymer price spike; partial price hikes taken |
| EBITDA (Consolidated) | ₹26.0 crore (23.6% margin) | Margin impacted by lower gross margin and higher commissioning/operating costs of new facilities |
| EBITDA (Standalone) | ₹24.2 crore | Reflects raw material pressure and new facility costs |
| Cash Profit (Consolidated) | ₹25.6 crore | +18% YoY; demonstrates underlying cash generation strength |
| Cash Profit (Standalone) | ₹25.2 crore | +18% YoY; steady improvement in cash profitability |
| Gross Debt | ₹384 crore | Peak year for depreciation and interest as new capex absorbs costs |
| Net Debt | ~₹333-344 crore | Interest run rate ~₹24 crore/year; expected to decline from FY28 |
| Depreciation (Q1 Standalone) | ₹24.5 crore | Includes ₹14 crore Parshla + ₹4 crore Amtra; FY27 project ₹105-110 crore (peak) |
| Raw Material Cost Escalation | +25-50% | Polymer price spike hitting gross margin; ~450-500 bps direct impact on material margin |
| Price Increase Taken | Marginal (domestic only) | Export price increase ~0%; relying on rupee depreciation for export realization |
Geographic & Segment Commentary
Domestic India: Revenue grew 17% YoY in Q1FY27, driven by distribution strength and improved demand momentum. Management noted a "meaningful revival" in customer inquiries across end industries and expects the domestic market to return to pre-Covid growth levels of 9%. Growth was predominantly from the existing product portfolio with negligible contribution from incremental capacities, leaving headroom for further acceleration. The government/GeM portal segment (15-20% of the ₹1,200-1,300 crore domestic market) has seen reduced Tarsons share due to abolition of rate contracts.
Exports (India-based): Recovered strongly with 29% YoY growth in Q1FY27. Customer inquiries and order pipelines improved, supported by trade fair participation and new customer wins. White-labeling is emerging as a key growth driver. However, management cautioned on lumpiness from shipment timing - vessels and shipping dates are buyer-nominated and outside company control, so quarterly export numbers can be volatile.
Germany (Nurbe Subsidiary): Revenue grew ~6% YoY in constant currency, described as "resilient" in a challenging environment. Nurbe operates ~70% in Germany and ~30% rest of EU. Management sees significant runway through integration with Tarsons - cross-selling Tarsons manufactured products through Nurbe's network and expanding Nurbe's geographic presence beyond Germany.
New Facilities (Parshla & Amtra): Parshla and Amtra are in final commissioning phase; trial runs underway across select product lines. Some revenue contribution in Q1FY27 from existing products (e.g., bioprocess containers, media bottles already commercialized) but cell culture products not yet contributing. Full commissioning expected in Q2FY27 with meaningful revenue from H2FY27.
Company-Specific & Strategic Commentary
Capacity Expansion Completed: The largest-ever capex program (four-year, ~₹1,164 crore TWIP) is in its final phase with substantial part commissioned. Remaining ~₹160 crore of CWIP to be capitalized in Q2-Q3FY27. No major new capex planned; only maintenance capex of ₹20-25 crore annually. Fixed asset turnover expected at ~0.8x, implying ~₹400 crore incremental revenue potential over the entire capex plan.
New Product Portfolio: Cell culture consumables, bioprocess containers, and media bottles are the key new categories. Bioprocess/roller bottles are "fully commercialized and selling in the market" with robust product quality. Cell culture targeted for a meaningful Indian market share over 2-3 years. New product portfolio (including cell culture) expected to generate ₹65-70 crore revenue in FY28.
Sales Organization Strengthening: New SMB-level (senior management) hire for revenue and strategy, plus mid-to-senior level hires reporting to this leader. Sales teams being built domestically and for international geographies (initially India-based for overseas markets, with local hiring as revenue scales).
Nurbe Integration: Cross-selling Tarsons products through Nurbe's established German network identified as a "meaningful opportunity." Management upgrading Nurbe's sales team quality with experienced industry hires. Strategy targets expanded geographic presence (beyond Germany) and broader product portfolio.
Export Pricing Strategy: In international markets, price increases were kept close to zero due to competitive intensity and strong global players maintaining prices. The company relies on rupee depreciation for better realizations to offset higher input costs.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue Growth | ~15% achievable | Q1 already exceeded 15%; demand recovery observed; depends on new product ramp-up and external environment |
| Parshla & Amtra Commissioning | Full commissioning in Q2FY27 | Trial runs underway; revenue contribution begins H2FY27 |
| Parshla & Amtra Revenue Share (FY28) | 20-25% of standalone revenues | Ramp-up as utilization improves through FY27 into FY28 |
| New Product Portfolio Revenue (FY28) | ₹65-70 crore | Includes cell culture, bioprocess containers, media bottles |
| FY27 Depreciation | ₹105-110 crore (peak year) | To decline from FY28; absorbs new capex costs |
| Debt Reduction (FY27) | ₹40-50 crore | Via loan repayments and LC conversions |
| Maintenance Capex | ₹20-25 crore annually | No major new capex planned after current program completes |
| Total Revenue Potential | ₹750-800 crore | Based on fixed asset turnover of ~0.8x across ~₹1,164 crore capex |
| Gross Margin | Similar to Q1 levels near-term | Directly tied to volatile raw material prices; 450-500 bps impact if sustained |
Risks & Constraints
| Risk | Context |
|---|---|
| Raw Material Price Volatility | Polymer prices spiked 25-50%, with volatility persisting (peaked ~6 weeks ago, dipped, then rising again). Management cannot predict gross margin trajectory with certainty; 450-500 bps direct hit if sustained. |
| Limited Pricing Power Internationally | Export price increases ~0% due to competitive intensity from global players and Chinese competitors. Relying on rupee depreciation for offset; cannot fully pass on input cost increases. |
| Geopolitical/Logistics Disruptions | West Asia crisis affecting vessel availability and shipping schedules; shipment timing is buyer-controlled, causing quarterly lumpiness in export revenue. |
| Tariff Uncertainty | Rumors of tariffs on India from US border the market; tariffs at 10% currently not the main hurdle (logistics and input costs are), but outlook remains uncertain. |
| Export Market Volatility | US/European markets remain challenging; demand recovery signs visible but sustainability dependent on macro environment. |
| New Facility Ramp-Up Execution | Commissioning delays (Parshla shifted from start of FY27 to Q2-Q3) due to external factors, supplier challenges, and scale. Profitability absorption depends on utilization ramp. |
| Government Business Erosion | Abolition of rate contracts and shift to GeM bidding reduced Tarsons' share of government/institutional business in the domestic market. |
Q&A Highlights
Export Strategy vs Global Competition
- Question: How does Tarsons compete against global players with stronger balance sheets and larger SKU portfolios? (Rushabh Shah)
- Answer: Tarsons positions as a lean, high-quality producer at competitive prices targeting segments global peers don't focus on. The bigger challenges are geopolitical (wars, freight costs, tariffs) rather than competition which has existed since pre-Covid. Differentiation in labware is driven by product quality, price, and consistent supply of a large portfolio over time. (Aryan Sehgal)
Parshla Commissioning Delay
- Question: Why has Parshla commercial commissioning been delayed from start of FY27 to H2FY27? (Jasdeep Walia)
- Answer: Delay driven by scale and number of projects; depends on external factors (international engineering teams, machine installation). Standard operational issues across different suppliers compounded by volume of lines. Most products commissioned; select lines completing in Q2. Parshla contributed to Q1 revenue from existing products (bioprocess containers, media bottles), not cell culture. (Aryan Sehgal)
Raw Material Prices and Margin Outlook
- Question: Are raw material prices coming down from the March-April peak, and what price hikes were taken? (Aditya)
- Answer: Input costs peaked ~6 weeks ago, dipped sharply over 10 days with peace deal, then rose again over last 2 weeks. Very volatile, tracked week-on-week. Export price hikes close to zero (relying on rupee depreciation); domestic price increase was marginal - not covering entire input cost escalation. Gross margin bottom difficult to determine since erosion is purely external (input costs), not internal operational issues. (Aryan Sehgal)
Domestic Market Demand Recovery
- Question: Is domestic market growth returning to the pre-Covid ~8-9% level? (Aditya)
- Answer: "Almost there" - late single digit growth consistent with pre-Covid levels. Strategy: leverage strong base for wallet share in existing products, penetrate cell culture market deeply over 2-3 years, pivot into specialized biopharma products (supported by Biopharma Shakti scheme), then ramp up bench-top equipment space. (Aryan Sehgal)
Capex Completion and Revenue Potential
- Question: How much capex remains, and what sales are possible at peak utilization? (Rahul Jain)
- Answer: Pending CWIP ~₹160 crore (not new capex, related to existing plan), to be capitalized within Q2-Q3. Fixed asset turnover at ~0.8x implies ~₹400 crore incremental revenue from the 4-year capex plan, that's total revenue potential of ~₹750-800 crore. Interest run rate ~₹24 crore/year continues in FY27, declining in FY28. (Santosh Agarwal, Aryan Sehgal)
Growth Outlook Beyond 15%
- Question: Does 20-25% growth depend on cell culture success? (Kiran)
- Answer: 15% growth is sustainable base level given market growth; the delta above 15% depends on successful new product launches (cell culture being sensitive with established players requiring time for SOP adoption) and external international environment support. Growth will not be "overly aggressive" to maintain sustainability. White-labeling included in export growth plans. (Aryan Sehgal)
Nurbe Integration and Market Opportunity
- Question: What is the market size Nurbe addresses and what percentage can be served by Tarsons manufacturing? (Nikhil Upadhyay)
- Answer: Nurbe is ~70% German, ~30% EU (95% of international within EU). Strong distributor/direct sales network in Germany, focused on select niche products. Growth opportunities: expanding geographic presence beyond Germany, broadening product portfolio from Tarsons offering, and backward manufacturing. Sales team strengthened in quality (experienced industry hires) rather than quantity. (Aryan Sehgal)
Government Business and GeM Portal Impact
- Question: Has Tarsons' share in government business declined due to GeM marketplace? (Aditya)
- Answer: Share declined - abolition of rate contracts in research institutes forced GeM bidding every purchase. Government market estimated at ~15-20% (best case) of the ₹1,200-1,300 crore domestic market. No government grants/incentives received for Parshla/Amtra capex. (Aryan Sehgal)
Key Takeaway
Tarsons Products delivered a strong Q1 FY27 with consolidated revenue of ₹110.2 crore (+20.7% YoY) and standalone revenue of ₹86.1 crore (+21% YoY), the highest ever Q1 standalone figure, driven by domestic growth of 17% and an export rebound of 29%. Gross margins were pressured to 67.1% by a 25-50% spike in polymer prices, with EBITDA margin at 23.6% and cash profit growing 18% to ₹25.6 crore. Management guided FY27 revenue growth of ~15% as achievable, with Parshla and Amtra fully commissioning in Q2 and contributing 20-25% of standalone revenue in FY28, alongside ₹65-70 crore from the new product portfolio. Depreciation is expected to peak at ₹105-110 crore in FY27 before declining, with net debt reducing ₹40-50 crore this year. Strategy centers on cell culture market penetration, export white-labeling, and Nurbe integration for cross-selling. Key watch points remain raw material volatility (a 450-500 bps gross margin swing risk), tariff uncertainty, shipment lumpiness in exports, and successful commissioning of remaining capex lines; the medium-term revenue potential stands at ₹750-800 crore with management optimistic on accelerating growth from FY28 as operating leverage kicks in.